<DOC>
	<DOCNO>NCT00837629</DOCNO>
	<brief_summary>This non-interventional study analyse therapeutic effectiveness patient severe COPD follow generally accept 12-week treatment period Symbicort Turbuhaler , could anyhow shorten extended physician 's discretion .</brief_summary>
	<brief_title>Evaluation Symbicort® Turbuhaler® ( Budesonide/Formoterol ) Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>non pregnant female COPD persistent symptom spite regular bronchodilator therapy Naive fix combination treat patient include patient already Symbicort Turbuhaler Hypersensitivity budesonide , formoterol inhale lactose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
</DOC>